

UKCPA

CLINICAL PHARMACY ASSOCIATION

Clinical Pharmacy Training Day

Agenda and session information

23 November 2017

The Queens Hotel, Leeds



UKCPA Members Registration Fee: £ 70
Non-Members Registration Fee: £170

This event has been financially supported by the pharmaceutical industry. Please refer to the back page for a list of sponsors. Sponsors have had no input into the content of the meeting. Promotional stands from sponsors will be exhibited at this event.

Clinical Pharmacy Training Day: Agenda

23 November 2017, Leeds

09.30 – 09.55	Registration Exhibition and refreshments	Hotel Foyer Palm Court
09.55 – 10.10	Introduction and welcome	Syndicate rooms
10.10 – 11.10	Session 1 Stream 1: Asthma: An update on current treatment Stream 2: Reducing falls and fractures in older people Stream 3: Effective prescribing in eczema Stream 4: Management approaches for patients with cancer and co-morbidities; diabetes, cardiac and mental health issues	
11.10 – 11.30	Exhibition, networking and refreshments	Palm Court
11.30 – 12.30	Session 2 Stream 1: Recent developments in COPD treatment Stream 2: Reducing medicines burden and de-prescribing Stream 3: ABC of anticoagulation Stream 4: Drugs in liver disease	
12.30 – 13.15	Exhibition, networking and lunch – including Inhaler Technique Demonstration	Palm Court
13.15 – 14.15	Session 3 Stream 1: Medication use in pregnancy Stream 2: The post-operative surgical patient Stream 3: ABC of heart failure Stream 4: Safe administration of oral and enteral liquid medicines	
14.15 – 14.20	Transition time to move between workshops	
14.20 – 15.20	Session 4 Stream 1: Medication use in breastfeeding Stream 2: Urinary tract infections Stream 3: Stroke: What it is, what it's not and the role of the stroke pharmacist Stream 4: Medication safety in theatres	
15.20 – 15.35	Exhibition networking and refreshments	Palm Court
15.35 – 16.35	Session 5 Stream 1: Multiple Sclerosis: What to look out for, treatments, therapies and future developments Stream 2: Infection emergencies Stream 3: ABC of atrial fibrillation Stream 4: Insulin: New risks in diabetes	
16.35 – 16.50	Summary and close	Syndicate rooms

Delegates attend one topic stream per session slot

To book, please register online here: <http://bit.ly/1Vb3y04>

Sessions have been indicated as:

F Foundation

CA Core Advanced

Session 1: 10.10 – 11.10		
Title	Speaker/s	Overview and learning outcomes
<p>Stream 1: Asthma: An update on current treatment</p> <p>F CA</p>	<p>Professor Anna Murphy, Consultant Respiratory Pharmacist, University Hospitals of Leicester NHS Trust, Honorary Visiting Professor, De Montfort University, Leicester and UKCPA Respiratory Group Committee Member</p>	<p>At the end of this session, participants should be able to:</p> <ul style="list-style-type: none"> • Demonstrate knowledge of management of asthma and chronic asthma and chronic obstructive pulmonary disease (COPD) including oxygen, inhaler technique, physiotherapy and the national/British Thoracic Society (BTS) guidance. • Asthma (acute and chronic) 1. List the commonly used drugs, usual doses and routes of administration. 2. Describe place in therapy of each drug wrt guidelines/evidence. 3. Describe the mechanism of action and pharmacokinetics of drugs used. 4. Adverse effects: identify & advise appropriate action to manage/prevent. • Asthma (acute and chronic) 1. Drug- drug, drug-patient e.g. drug handling in the elderly, drug- disease interactions: identify, prioritise and manage. 2. Treatment targets: identify, prioritise, manage. 3. Optimise patient concordance. • Asthma (acute and chronic) 1. Identify monitoring parameters. 2. Prioritise monitoring parameters. 3. Advise suitable actions to ensure appropriate monitoring. • Advise on the optimal guideline management of asthma • Describe the role of new medicines in asthma
<p>Stream 2: Reducing falls and fractures in older people</p> <p>F</p>	<p>Heather Smith, Consultant Pharmacist: Older People / Interfaces of Care, Medicines Management & Pharmacy Services, Leeds Teaching Hospitals NHS Trust</p>	<p>At the end of this session, participants should be able to:</p> <ul style="list-style-type: none"> • Outline which medicines have the potential to cause falls and the mechanism behind this • Discuss why older people are at higher risk of falls and fractures from falls • Explain how to reduce falls and fractures in older people
<p>Stream 3: Effective prescribing in eczema</p> <p>F</p>	<p>Dr Christine Clark, freelance medical writer and independent pharmaceutical consultant specialising in dermatology</p>	<p>At the end of this session, participants should be able to:</p> <ul style="list-style-type: none"> • Describe the current thinking regarding the pathology of eczema • Describe the current treatment recommendations with reference to NICE and SIGN guidelines • Identify common pitfalls in treatment and how to overcome them • Describe the use of the POEM (patient oriented eczema measure) • Describe the place of dupilumab and crisaborole in eczema treatment
<p>Stream 4: Management approaches for patients with cancer and co-morbidities; diabetes, cardiac and mental health issues</p> <p>CA</p>	<p>Mark Evans, Associate Chief Pharmacist Clinical Services, The Royal Marsden NHS Foundation Trust</p> <p>Islam Elkonaissi, Clinical & Chemotherapy Services Pharmacist, The Royal Marsden NHS Foundation Trust and UKCPA General Committee Member</p>	<p>At the end of this session, participants should be able to:</p> <ul style="list-style-type: none"> • Be able to list the major prescribing rules for patients with cancer and co-morbidities and list specific sources of information. • Understand the pharmaceutical issues of managing a patient with cancer and diabetes • Understand the pharmaceutical issues of managing a patient with cardiac problems • Understand the pharmaceutical issues of managing a patient with cancer and mental health issues • Apply learning to practice through case based discussions

Sessions have been indicated as:

F Foundation

CA Core Advanced

Session 2: 11.30 – 12.30		
Title	Speaker/s	Overview and learning outcomes
<p>Stream 1: Recent developments in COPD treatment</p> <p>F CA</p>	<p>Grainne d'Ancona, Consultant Pharmacist, Acute Medicine, Guy's and St Thomas' NHS Foundation Trust and UKCPA Respiratory Group Committee Member</p>	<p>At the end of this session, participants should be able to:</p> <ul style="list-style-type: none"> • Explain spirometry to confirm or refute a diagnosis of COPD • Discuss the management of chronic obstructive pulmonary disease (COPD) using pharmacological and non-pharmacological therapies • Identify patient monitoring parameters. Discuss changes that may suggest an exacerbation of COPD • List the differential diagnoses associated with breathlessness • List the commonly used classes of drugs, and describe their place in therapy. Recognise the side effects of these treatments and identify & advise appropriate action to manage/ prevent them • Compare the evidence for new drug therapies and contrast to existing therapies
<p>Stream 2: Reducing medicines burden and de-prescribing</p> <p>CA</p>	<p>Helen Whiteside, Lead Clinical Pharmacist In General Practice, Five Towns Federation, Wakefield</p>	<p>The session will give an overview of the impact of medicines burden and current polypharmacy management guidelines. Case based discussions will focus on holistic medication review, opportunities for and practicalities of de-prescribing.</p> <p>At the end of this session, participants should be able to:</p> <ul style="list-style-type: none"> • Discuss the current medicines burden and impact this has on an individual and carers • Explain the reasons behind polypharmacy • Identify the barriers and enablers to, opportunities for and practicalities of de-prescribing • Discuss the current polypharmacy management guidelines
<p>Stream 3: ABC of anticoagulation</p> <p>F</p>	<p>Katherine Stirling, Consultant Pharmacist Anticoagulation and Thrombosis, Leeds Teaching Hospitals NHS Trust and UKCPA Haemostasis, Anticoagulation and Thrombosis Group Committee Member</p>	<p>At the end of this session, participants should be able to:</p> <ul style="list-style-type: none"> • More confidently answer questions on choice and monitoring of anticoagulation plus risks and benefits in specific patient groups
<p>Stream 4: Drugs in liver disease</p> <p>F</p>	<p>Dan Greer, Lecturer-Practitioner, University of Leeds and Leeds Teaching Hospitals and UKCPA Gastroenterology & Hepatology Group Committee Member</p>	<p>The aim of this session is to enable attendees to apply the principles of drug choice in liver disease considering the relevant adverse effect profiles of drugs and the pharmacokinetic changes in liver disease.</p> <p>At the end of this session, participants should be able to:</p> <ul style="list-style-type: none"> • Apply the principles of drug choice in Liver disease considering: <ul style="list-style-type: none"> • Relevant adverse effect profiles of drugs • Pharmacokinetic changes in Liver disease

Workshop: 12.40 – 13.10		
Lunchtime Inhaler Technique Demonstration	<p>Professor Anna Murphy (please see details under Session 1, Stream 1),</p> <p>Grainne d’Ancona (please see details under Session 2, Stream 1)</p> <p>Toby Capstick, Lead Respiratory Pharmacist, Leeds Teaching Hospitals NHS Trust and UKCPA Respiratory Group Committee Chair</p>	<p>The ability to use inhaler devices correctly is critical to ensuring that patients with asthma and COPD maximise the benefits of their treatment. Over the past few years, many new inhaler devices have been launched in the UK market, in addition to the number of devices currently available. This range of inhaler devices creates complexity to the management of respiratory diseases. Pharmacists are ideally placed to train both patients and other healthcare professionals on how to use these devices and optimise patient care.</p> <p>This session will be suitable for foundation-level pharmacists, specialist and non-specialist pharmacists who would like to learn about how to use different inhaler devices, in order to teach their patients.</p>




Sessions have been indicated as:



Foundation



Core Advanced

Session 3: 13.15 – 14.15		
Title	Speaker/s	Overview and learning outcomes
<p>Stream 1: Medication use in pregnancy</p> <p></p>	<p>Christina Nurmahi, Women & Newborn Care Group Lead Pharmacist, University Hospital Southampton NHS Foundation Trust and UKCPA Women’s Health Group Committee Member</p>	<p>At the end of this session, participants should be able to:</p> <ul style="list-style-type: none"> • Describe the stages of foetal development and some of the risks associated with drug exposure throughout pregnancy • Explain the factors that influence drug handling in pregnancy including the impact of physiological changes in pregnancy • Discuss the general principles of prescribing in pregnancy and how to reduce risk • Discuss morbidity and mortality in pregnancy and the management of some of the high risk groups identified e.g. Hypertension, Sepsis, VTE, Mental Health
<p>Stream 2: The post-operative surgical patient</p> <p> </p>	<p>Neetu Bansal, Enhanced Recovery Pharmacist, Adult Surgery, Central Manchester and Manchester Children’s University Hospital and UKCPA Surgery and Theatres Group Committee Member</p>	<p>At the end of this session, participants should be able to:</p> <ul style="list-style-type: none"> • Discuss commonly undertaken gastrointestinal procedures (e.g. following bariatric surgery, ileostomy/colostomy formation, intestinal failure), the implications of altered anatomy for enteral drug therapy, surgical management and pharmacological treatment associated with these procedures • Explain the implications and management of the nil-by-mouth state in the post-operative period • Describe the common complications of surgical procedures and the role of medicines management in minimising these after surgery • Describe the key aspects of good medicines management in the post-operative period and explain how co-operation in the multi-professional team across boundaries can optimise surgical recovery in this crucial period • Describe the interplay between health and social care and its impact on pharmaceutical care. • Demonstrate knowledge of agencies involved in community care and the effect of this on medicines management. • Identify the barriers to optimising medicines when working across healthcare interfaces and employ strategies to overcome them to optimise patient outcomes and avoid readmissions after surgery

Sessions have been indicated as:

F Foundation

CA Core Advanced

Session 3 cont.d: 13.15 – 14.15		
Title	Speaker/s	Overview and learning outcomes
<p>Stream 3: ABC of heart failure</p> <p>F</p>	<p>Dr Rani Khatib, Consultant Pharmacist in Cardiology & Cardiovascular Research, Leeds Teaching Hospitals NHS Trust and UKCPA Cardiac Group Committee Member</p>	<p>At the end of this session, participants should be able to:</p> <ul style="list-style-type: none"> • Discuss the underlying pathophysiology of heart failure • Identify heart failure symptoms and be aware of the NYHA tool and its relation to assessment of the patient's symptoms • Discuss the pharmacological management of heart failure • Describe recent therapies of heart failure • List the Medicines Optimisation needs for patients with heart failure • Develop Medicines Optimisation care plans for patients with Heart Failure
<p>Stream 4: Safe administration of oral and enteral liquid medicines</p> <p>F CA</p>	<p>Surinder Ahuja, Medicines Evaluation Pharmacist, Rotherham NHS Foundation Trust</p>	<p>• At the end of this session, participants should be able to:</p> <ul style="list-style-type: none"> • Discuss how factors relating to patients, healthcare professionals, workplace design and the design of medication processes contribute to medication errors • Describe the different types of tubes/methods that are used to deliver enteral nutrition and factors that need to be taken into consideration when advising on the administration of drugs via enteral feeding tubes • Discuss the pharmaceutical issues around administration of medication through nasogastric, nasojejunal, gastrostomy and jejunostomy tubes • Discuss the risk relating to patients, medicines and processes in relatively high risk groups • Find the literature and resources available for managing medicines associated risk • Evaluate the contribution product design makes to patient safety for example packaging and device technology • Identify when appropriate to report incidents or adverse effects • Outline the systems in place to prevent wrong route Never Events associated with oral/enteral liquid medicines

Sessions have been indicated as:

F Foundation

CA Core Advanced

Session 4: 14.20 – 15.20		
Title	Speaker/s	Overview and learning outcomes
Stream 1: Medication use in breastfeeding F	Nicky Moya , Directorate Pharmacist Neonatal and Women's Services, Portsmouth Hospitals NHS Trust and UKCPA Women's Health Group Committee Member	At the end of this session, participants should be able to: <ul style="list-style-type: none"> • Describe the principles of transfer of drugs into breast milk and relative infant dose • Explain the considerations of the risk/benefit to mother/infant and interpretation of suitability in preterm and sick babies • Signpost to resources available to ascertain the suitability of drugs in breastfeeding • Discuss common maternal medications for conditions including asthma, hypertension, epilepsy, infection and depression and those drugs that are recognised as safe in transfer to breastmilk
Stream 2: Urinary tract infections F	Ana Megias Bas , Senior Pharmacist – Antimicrobials/Acute Surgery, Jull & East Yorkshire Hospitals NHS Trust	At the end of this session, participants should be able to: <ul style="list-style-type: none"> • Discuss the epidemiology, pathology, treatment, diagnosis and management of urinary tract infections and catheter associated urinary tract infections
Stream 3: Stroke: What it is, what it's not and the role of the stroke pharmacist F CA	Paresh Parmar , Lead Care of Older People and Stroke Pharmacist, Northwick Park Hospital	This session will provide an overview of the underlying pathophysiology of stroke, the acute management and the principle aims of treatment as described in recent guideline recommendations from the Royal college of Physicians and the role of the pharmacist in dysphagia, secondary prevention and signposting. <p>At the end of this session, participants should be able to:</p> <ul style="list-style-type: none"> • Describe the underlying pathophysiology of stroke • Describe the acute management of stroke treatment (Ischemic and hemorrhagic) • Describe the pharmacological and non-pharmacological strategies employed in the management of stroke • Implement guideline recommendations when advising on the management of stroke
Stream 4: Medication safety in theatres F CA	Gillian Cavell , Consultant Pharmacist, Medication Safety, King's College Hospital NHS Foundation Trust and UKCPA Medicines Safety and Quality Group Committee Chair	At the end of this session, participants should be able to: <ul style="list-style-type: none"> • Describe how factors relating to patients, healthcare professionals, workplace design and the design of medication processes contribute to medication errors • Discuss the risk relating to patients, medicines and processes in relatively high risk groups • Find the literature and resources available for managing medicines associated risk • Evaluate the contribution product design makes to patient safety for example packaging and device technology • Identify when appropriate to report incidents or adverse effects. • Discuss the uses and limitations of the NPSA risk assessment tool for the preparation of injectable medicines

Sessions have been indicated as:

F Foundation

CA Core Advanced

Session 5: 15.35 – 16.35		
Title	Speaker/s	Overview and learning outcomes
<p>Stream 1: Multiple Sclerosis: What to look out for, treatments, therapies and future developments</p> <p>CA</p>	<p>Joela Mathews, Lead Pharmacist for Neurosciences, Barts Health NHS Trust and UKCPA Neurosciences Group Committee Education Lead</p>	<p>At the end of this session, participants should be able to:</p> <ul style="list-style-type: none"> • Describe the clinical features of multiple sclerosis, • Discuss the management of specific impairments and disabilities arising in multiple sclerosis (MS). • Describe the role of disease modifying drugs, symptomatic treatments and therapies for MS. • Outline the disease modifying drugs that are currently in phase 3 trials and their place in therapy
<p>Stream 2: Infection emergencies</p> <p>F</p>	<p>Jamie Cheong, Specialist Pharmacist, Antimicrobial, Royal Brompton & Harefield NHS Foundation Trust</p>	<p>The aim of this session is to develop participants knowledge on advising on antimicrobial therapy for infection emergencies</p> <p>At the end of this session, participants should be able to:</p> <ul style="list-style-type: none"> • Identify signs and symptoms of some infection emergencies • Name primary organisms that can cause these infections • Recommend first line treatment
<p>Stream 3: ABC of atrial fibrillation</p> <p>F</p>	<p>Nazish Khan, Principal Pharmacist, Cardiac Services, The Royal Wolverhampton NHS Trust and UKCPA Cardiac Group Committee Member</p>	<p>The aim of this session is to provide an overview of the underlying pathophysiology of atrial fibrillation and the principle aims of treatment as described in recent guideline recommendations.</p> <p>By the end of this session participants should be able to:</p> <ul style="list-style-type: none"> • Describe the underlying pathophysiology of atrial fibrillation • Describe the risk stratification tools utilised to determine the treatment strategy to apply when managing patients with a diagnosis of atrial fibrillation • Describe the pharmacological and non-pharmacological strategies employed in the management of atrial fibrillation • Understand and implement guideline recommendations when advising on the management of atrial fibrillation
<p>Stream 4: Insulin: New risks in diabetes</p> <p>CA</p>	<p>Naomi Burns, Medicines Safety Pharmacist, Western Sussex Hospitals NHS Foundation Trust</p>	<p>At the end of this session, participants should be able to:</p> <ul style="list-style-type: none"> • Identify new risks with the introduction of new insulin formulations • Identify new risks in the prescribing of insulin with electronic prescribing systems • Identify risks associated with the withdrawing of insulin from pen devices • Evaluate the impact following national guidance on the use of withdrawing insulin from pen devices • Utilise expert knowledge in identifying solutions to the risks posed

This event has been financially supported by the pharmaceutical industry.
Sponsors have had no input into the content of the meeting. Industry supporters of this event are:



(Correct at time of print)

Promotional stands from the above sponsors will be exhibited at this training day.
Other pharmaceutical companies have been invited to support this event.

For further information, please contact:

UKCPA
Suite 1.2F, Lyn House
39 The Parade
Oadby, Leicester
LE2 5BB

Tel: 0116 2714894
Email: admin@ukcpa.com

www.ukclinicalpharmacy.org

To book your place, please register online here: <http://bit.ly/1Vb3y04>